The global head and neck squamous cell carcinoma market is set for steady growth, driven by advancements in treatment options, increasing awareness of early cancer detection, and rising demand for ...

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...

Everest Medicines has dosed the first participant in a Phase I clinical trial of its tumour-associated antigen (TAA) cancer ...

Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...

Esophageal cancer occurring in patients with head and neck squamous cell carcinoma (HNSCC) represents a critical clinical challenge, as these secondary tumours notably worsen patient prognosis. Owing ...

Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer Newly diagnosed patients with cT2-4N0-2M0 HNC were ...

A prospective, single-arm, phase II study of adebrelimab plus carboplatin and albumin-bound taxanol as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell ...

In a national cohort study of patients with resectable head and neck squamous cell carcinoma (HNSCC), the number receiving neoadjuvant immunotherapy began to rise markedly in 2013, while use of ...

Bicara Therapeutics announced the publication of an abstract with early data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa ...

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW ...